Last reviewed · How we verify

Buffered Articaine Hydrochloride + Epinephrine

Ohio State University · FDA-approved active Small molecule

Buffered articaine hydrochloride is a local anesthetic that blocks sodium channels in nerve cell membranes, while epinephrine is a vasoconstrictor that prolongs anesthetic duration and reduces bleeding.

Buffered articaine hydrochloride is a local anesthetic that blocks sodium channels in nerve cell membranes, while epinephrine is a vasoconstrictor that prolongs anesthetic duration and reduces bleeding. Used for Local and regional anesthesia for dental and oral surgical procedures.

At a glance

Generic nameBuffered Articaine Hydrochloride + Epinephrine
SponsorOhio State University
Drug classLocal anesthetic with vasoconstrictor
TargetVoltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)
ModalitySmall molecule
Therapeutic areaAnesthesiology / Dentistry
PhaseFDA-approved

Mechanism of action

Articaine is an amide-type local anesthetic that reversibly inhibits sodium influx into nerve cells, preventing depolarization and action potential propagation. The addition of epinephrine causes vasoconstriction of local blood vessels, which slows systemic absorption of the anesthetic, extends its duration of action, and reduces intraoperative bleeding. Buffering the solution optimizes pH to enhance onset speed and efficacy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results